Stay updated with breaking news from Not Reached. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Intermediary results of high dose PDC*lung01 combined with pembrolizumab show mild safety profile, immunological activity and promising tumor response in Non-Small Cell Lung Cancer patientsCombination of high dose PDC*lung01 with pembrolizumab in 19 evaluable patients resulted in objective response rate of 63.2% and...
LIÈGE, Belgium & GRENOBLE, France, April 08, 2024--PDC*line Pharma, a clinical-stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, today announces the interim results from the last cohort of patients in its phase I/II clinical trial (PDC-LUNG-101, NCT03970746) with PDC*lung01.
In navigating the aftermath of an Houston Oilfield Accident Attorney, securing adept legal representation is paramount. The complexities demand not just legal proficiency but also compassion. From initiating a lawsuit to potential trial proceedings, understanding the legal journey empowers victims.
ATHENA study evaluating Rubraca monotherapy versus placebo (ATHENA-MONO) successfully achieved the primary endpoint of improved PFS in both populations in the primary efficacy analyses: HRD-positive
Approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer1In the Phase 3 CheckMate -816 trial, Opdivo plus platinum-doublet chemotherapy significantly improved event-free survival and pathologic complete response compared to platinum-doublet chemotherapy al...